A Four-Group Urine Risk Classifier for Predicting Outcome in Prostate Cancer Patients.
View/ Open
Date
2019-05-20ICR Author
Author
Connell, SP
Hanna, M
McCarthy, F
Hurst, R
Webb, M
Curley, H
Walker, H
Mills, R
Ball, RY
Sanda, MG
Pellegrini, KL
Patil, D
Perry, AS
Schalken, J
Pandha, H
Whitaker, H
Dennis, N
Stuttle, C
Mills, IG
Guldvik, I
Movember GAP1 Urine Biomarker Consortium
Parker, C
Brewer, DS
Cooper, CS
Clark, J
Type
Journal Article
Metadata
Show full item recordAbstract
Objectives To develop a risk classifier using urine-derived extracellular vesicle RNA (UEV-RNA) capable of providing diagnostic information of disease status prior to biopsy, and prognostic information for men on active surveillance (AS).Patients and methods Post-digital rectal examination UEV-RNA expression profiles from urine (n = 535, multiple centres) were interrogated with a curated NanoString panel. A LASSO-based Continuation-Ratio model was built to generate four Prostate-Urine-Risk (PUR) signatures for predicting the probability of normal tissue (PUR-1), D'Amico Low-risk (PUR-2), Intermediate-risk (PUR-3), and High-risk (PUR-4) PCa. This model was applied to a test cohort (n = 177) for diagnostic evaluation, and to an AS sub-cohort (n = 87) for prognostic evaluation.Results Each PUR signature was significantly associated with its corresponding clinical category (p<0.001). PUR-4 status predicted the presence of clinically significant Intermediate or High-risk disease, AUC = 0.77 (95% CI: 0.70-0.84). Application of PUR provided a net benefit over current clinical practice. In an AS sub-cohort (n=87), groups defined by PUR status and proportion of PUR-4 had a significant association with time to progression (p<0.001; IQR HR = 2.86, 95% CI:1.83-4.47). PUR-4, when utilised continuously, dichotomised patient groups with differential progression rates of 10% and 60% five years post-urine collection (p<0.001, HR = 8.23, 95% CI:3.26-20.81).Conclusion UEV-RNA can provide diagnostic information of aggressive PCa prior to biopsy, and prognostic information for men on AS. PUR represents a new & versatile biomarker that could result in substantial alterations to current treatment of PCa patients. This article is protected by copyright. All rights reserved.
Collections
Subject
Movember GAP1 Urine Biomarker Consortium
Language
eng
License start date
2019-05-20
Citation
BJU international, 2019